Table 3. WMHV is associated with longitudinal clinical dementia outcomes in females but not males.

A linear mixed effects model was utilized to test for interaction effects between WMHV^*visit time, Global18Futemetamol SUVR^*visit time on CDR-SB.

CDR sum of boxes
	β (Std. error)	β 95% Confidence Interval	Uncorrected p-value
Females
Intercept	4.69 (4.38)	(−3.93, 13.30)	0.29
Age (years)	−0.044 (0.044)	(−0.13, 0.04)	0.32
Visit Time	−0.73 (0.57)	(−1.85, 0.38)	0.20
Global18F-flutemetamol SUVR	0.34 (2.17)	(−3.94, 4.61)	0.88
WMHV	−0.18 (0.88)	(−0.75, 0.41)	0.56
Scanner Site (Site 2)	0.15 (0.87)	(−1.55, 1.86)	0.86
Scanner Site (Site 3)	−0.18 (0.88)	(−1.91, 1.55)	0.84
Scanner Site (Site 4)	0.90 (1.92)	(−2.88, 4.69)	0.64
Scanner Site (Site 5)	1.74 (2.01)	(−2.23, 5.70)	0.39
Scanner Site (Site 6)	−1.32 (0.73)	(−2.76, 0.12)	0.073
Visit Time * Global18F-flutemetamol SUVR	3.11 (0.60)	(1.92, 4.30)	5.50e-07 ***
Visit Time * WMHV	0.18 (0.072)	(0.04, 0.32)	0.014 *
Males
Intercept	0.90 (4.60)	(−8.18, 9.98)	0.85
Age (years)	0.0084 (0.053)	(−0.10, 0.11)	0.88
Visit Time	−1.48 (-0.71)	(−2.89, −.07)	0.039 *
Global18F-flutemetamol SUVR	2.68 (2.83)	(−2.90, 8.27)	0.34
WMHV	0.20 (0.42)	(−0.63, 1.02)	0.64
Scanner Site (Site 2)	−0.83 (1.10)	(−3.01, 1.35)	0.46
Scanner Site (Site 3)	−1.00 (1.51)	(−3.99, 1.98)	0.50
Scanner Site (Site 4)	0.39 (1.50)	(−2.58, 3.35)	0.80
Scanner Site (Site 5)	−0.30 (2.13)	(−4.51, 3.91)	0.89
CDR sum of boxes
Scanner Site (Site 6)	−0.31 (1.35)	(−2.99, 2.36)	0.82
Visit Time * Global18F-flutemetamol SUVR	2.99 (0.72)	(1.56, 4.41)	7.04e-05 ***
Visit Time * WMHV	0.019 (0.097)	(−0.17, 0.21)	0.84

^*p < 0.05,

^**p < 0.01,

^***p < 0.001